Related Experiment Video

Updated: Mar 10, 2026

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

7.6K

Engaging Cell Death Pathways for the Treatment of Rhabdomyosarcoma

Christine C Dobson1, Stephanie Langlois2, David Grynspan3

  • 1Molecular Biomedicine Program, Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada.

Critical Reviews in Oncogenesis
|December 6, 2016
PubMed

Insights

Rhabdomyosarcoma (RMS) is a childhood cancer resistant to therapy due to faulty apoptosis pathways. New treatments targeting these pathways offer hope for improved outcomes in pediatric patients.

Area of Science:

  • Pediatric Oncology
  • Cancer Biology
  • Molecular Medicine

Background:

  • Rhabdomyosarcoma (RMS) is the most common childhood soft tissue cancer.
  • Current therapies face challenges due to treatment resistance.
  • Apoptosis pathway defects are crucial in RMS pathogenesis and chemoresistance.

Purpose of the Study:

  • To highlight the need for understanding apoptotic resistance in RMS.
  • To identify potential therapeutic targets for improving RMS treatment outcomes.
  • To explore novel therapeutic strategies for RMS patients.

Main Methods:

  • Review of current literature on RMS and apoptosis.
  • Analysis of molecular mechanisms underlying chemoresistance in RMS.
  • Discussion of emerging therapeutic strategies targeting apoptosis.

Main Results:

  • Defects in apoptosis are a key factor in RMS development and treatment failure.
  • Targeting apoptotic pathways shows promise for overcoming resistance.
  • Combination therapies may enhance treatment efficacy.

Conclusions:

  • Understanding the molecular basis of apoptotic resistance is critical for advancing RMS therapy.
  • Novel approaches like IAP antagonists and immunotherapies could improve outcomes.
  • Personalized treatment strategies based on apoptotic profiles may benefit RMS patients.

More Related Videos

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics12:28

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

7.8K
Assessing Cell Viability and Death in 3D Spheroid Cultures of Cancer Cells10:33

Assessing Cell Viability and Death in 3D Spheroid Cultures of Cancer Cells

Published on: June 16, 2019

29.8K

Related Concept Videos

Overview of Cell Death01:30

Overview of Cell Death

Cell death is an essential process where the body gets rid of old or damaged cells. Cell proliferation and death need to be balanced, as an imbalance between the two may lead to cancer or autoimmune diseases.
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
10.8K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.0K
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Apoptosis01:30

Apoptosis

Apoptosis is a combination of two Greek words, 'apo' and 'ptosis,' meaning separation and falling off, respectively. Hippocrates used this word to describe gangrene, which was caused due to bandaging of fractured bones. Apoptosis was distinguished from necrosis in 1970 when John Kerr reported observations of morphological changes occurring during apoptosis. During one experiment, he observed that the disruption of blood supply to the liver tissue resulted in a size...
16.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K